All Clinical Trials:

ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Clinical Trial Protocol # ANBL1531 | Solid Tumors | Contact (714) 509-8646

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects > 1 and < 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Clinical Trial Protocol # JNJ-54767414 | Adolescents and Young Adults, Leukemia/Lymphom, Recurrent/Refractory Cancer | Contact (714) 509-8646

​AHEP1531, Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Clinical Trial Protocol # AHEP1531 | Solid Tumors | Contact (714) 509-8646

Janssen LYM3003/Sparkle; A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma

Clinical Trial Protocol # LYM3003 | Lymphoma | Contact (714) 509-8646

​ADVL1521 A Phase 2 Study of the MEK inhibitor Trametinib (IND#119346, NSC#763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Clinical Trial Protocol # ADVL1521 | Leukemia | Contact (714) 509-8646

​ACNS1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Clinical Trial Protocol # ACNS1422 | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646

​AALL15P1 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement.

Clinical Trial Protocol # AALL15P1 | Leukemia | Contact (714) 509-8646

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

Clinical Trial Protocol # Head Start IV | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646

AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Clinical Trial Protocol # AALL1631 | Leukemia | Contact (714) 509-8646

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Clinical Trial Protocol # AGCT1531 | Solid Tumors | Contact (714) 509-8646

ADVL1515 A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

Clinical Trial Protocol # ADVL1515 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

TINI, Total Therapy For Infants with Acute Lymphoblastic Leukemia (ALL) I

Clinical Trial Protocol # TINI | Leukemia | Contact (714) 509-8646

ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Clinical Trial Protocol # ALTE1621 | Late Effects | Contact (714) 509-8646

​Testicular Tissue Cryopreservation for Fertility Preservation in Patients Facing Infertility-causing Diseases or Treatment Regimens

Clinical Trial Protocol - Testicular Cryopreservation | Contact (714) 509-8646

ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

RXDX-101-03 – A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions (Igny

Clinical Trial Protocol # RXDX 101 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)

Clinical Trial Protocol # CDRB436G2201 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1722/Eisai E7389G000223: A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) an

Clinical Trial Protocol # ADVL1722 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after

Clinical Trial Protocol # AHOD1721 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1721/COG/Bayer 806946/19176: A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma

Clinical Trial Protocol # ADVL1721 | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

AALL1521, A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK PathwayMutant Acute Lymphoblastic Leukemia

Clinical Trial Protocol # AALL1521 | Adolescents and Young Adults, Leukemia | Contact (714) 509-8646

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Clinical Trial Protocol # ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to < 18 Years with Advance BRAF V600-Mutation Positive Solid Tumors

Clinical Trial Protocol # GSK Dabrafenib | Brain Tumor/ Centra Nervous System/Neuro-Oncology, Solid Tumors | Contact (714) 509-8646

Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646